Melanocortin Agonists Market
Number of pages: 100 | Report Format: PDF | Published date: May 11, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
5.9% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Type, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global melanocortin agonists market is expected to register a revenue CAGR of 5.9% during the forecast period from 2023 to 2031.
Melanocortin Agonists Market Fundamentals
Melanocortin agonists are drugs that activate melanocortin receptors in the brain and other tissues. These receptors are involved in the regulation of several physiological processes, including appetite, metabolism, and inflammation. Melanocortin agonists such as setmelanotide are primarily used to treat rare genetic disorders that cause severe obesity, such as pro-opiomelanocortin (POMC) deficiency, leptin receptor (LEPR) deficiency, and Bardet-Biedl syndrome (BBS). These disorders are characterized by a dysfunction in the melanocortin pathway, which leads to an imbalance in appetite regulation and energy homeostasis.
Melanocortins are a family of peptides produced by the body’s pituitary gland and other tissues. They are derived from a precursor protein called pro-opiomelanocortin (POMC) and regulate several physiological processes, including pigmentation, inflammation, and energy homeostasis. In the brain, melanocortins act as neurotransmitters and modulate various functions, including appetite, mood, and sexual behavior. Melanocortins exert their effects by binding to a family of G protein-coupled receptors, including the melanocortin 1 receptor (MC1R), melanocortin 2 receptor (MC2R), melanocortin 3 receptor (MC3R), melanocortin 4 receptor (MC4R), and melanocortin 5 receptor (MC5R).
The global melanocortin agonists industry analysis report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the melanocortin agonists market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the melanocortin agonists market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
Melanocortin Agonists Market Dynamics
The global prevalence of obesity has been steadily increasing over the past few decades, driven by factors such as sedentary lifestyles, unhealthy diets, and genetic predisposition. Melanocortin agonists such as setmelanotide offer a promising new treatment option for rare genetic disorders that cause severe obesity, contributing to the global melanocortin agonists market growth. For instance, according to the WHO’s factsheet of June 2021, obesity globally has tripled since 1975; in 2016, more than 1.9 billion adults were overweight. Moreover, as more research is conducted on melanocortin agonists and their potential applications in treating obesity and related metabolic disorders, awareness and acceptance of these drugs among healthcare providers and patients are growing. This is expected to drive demand for these drugs and support market growth.
Additionally, high cost, competition from other therapies, and regulatory challenges in developing nations are some restraints impeding the overall melanocortin agonists market growth.
Melanocortin Agonists Market Ecosystem
Melanocortin Agonists Market, by Drug Type
Melanocortin Agonists Market, by Application
Melanocortin Agonists Market by Drug Type
[54646]
Setmelonitide dominated the market with the largest revenue share in 2022. Setmelanotide is a drug that belongs to the class of melanocortin agonists and is used in treating obesity caused by rare genetic disorders. It is marketed under the brand name "Imcivree" and is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Setmelanotide works by activating specific receptors in the brain called melanocortin 4 receptors (MC4Rs), which play a key role in regulating food intake and energy balance. In patients with genetic disorders such as pro-opiomelanocortin (POMC) deficiency, leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome (BBS), MC4R signaling is disrupted, leading to uncontrolled appetite and severe obesity.
Additionally, continuous research and development activities are carried out to validate the safety and efficacy of setmelanotide. For instance, according to the Lancet Journal’s article of November 2022, setmelanotide showed a significant reduction in body weight in patients with Bardet-Biedl syndrome.
The market segmentation sections provide the melanocortin agonists market outlook in terms of the demarcation of different consumer groups. Market segmentation is the split of industry into subgroups depending on characteristics such as drug type and application. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data additionally helps in identifying potential melanocortin agonists market demand opportunities.
Melanocortin Agonists Market by Region
North America dominated the global localized temperature therapy products market with the largest revenue share in 2022, owing to the factors such as the high prevalence of obesity in the region, the availability of advanced healthcare infrastructure, and a favorable regulatory environment. Additionally, companies from the region are continuously involved in mergers, acquisitions, and partnerships is also expected to improve the melanocortin agonists market outlook.
Based on the regions, the global melanocortin agonists market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of melanocortin agonists industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level melanocortin agonists market overview.
Key Components of the Report
Melanocortin Agonists Market Competitive Landscape
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Melanocortin Agonists Market Strategic Developments
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Melanocortin agonists are a class of drugs that activate melanocortin receptors in the brain and other tissues.
Mergers, acquisitions, and partnerships are some of the strategies adopted by the key market players.
North American region will have the largest melanocortin agonists market size during the forecast period from 2023 to 2031.
The revenue CAGR of the melanocortin agonists market during the forecast period will be 5.9% from 2023 to 2031.
Growing awareness and acceptance of obesity and related metabolic disorders is the most prominent melanocortin agonists industry trend.
The high cost, competition from other therapies, and regulatory challenges in developing nations are some key challenges hampering the growth of the global melanocortin agonists market.
Increasing research and development and increasing prevalence of obesity are growth opportunities in the global melanocortin agonists market.
Some prominent players in the melanocortin agonists market are Palatin, Rhythm Pharmaceuticals Inc., and Clinuvel Pharmaceuticals Ltd.
The diagnosis segment has the highest share in the global melanocortin agonists market
*Insights on financial performance are subject to the availability of information in the public domain